Thyroxine suppression therapy for benign, non-functioning solitary thyroid nodules: a quality-effects meta-analysis

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Levothyroxine (LT4) suppressive therapy for solitary thyroid nodules lacks widespread advocacy due to controversial clinical efficacy and safety.
• Current guidelines do not widely recommend LT4 for this indication.

Purpose of the Study:

• To rigorously assess the efficacy of LT4 suppressive therapy in reducing solitary thyroid nodules.
• To provide a pooled estimate of LT4's effectiveness and associated risks.

Main Methods:

• A meta-analysis was conducted to synthesize existing data on LT4 therapy for solitary thyroid nodules.
• Rigorous statistical methods were employed to derive a pooled estimate of treatment efficacy.

Main Results:

• LT4 therapy was associated with a two-fold increase in the likelihood of thyroid nodule reduction.
• The number needed to treat (NNT) was calculated to be 6, indicating a 50% decrease in cancer risk upon nodule reduction.
• Adverse events associated with low-level LT4 suppression were found to be infrequent.

Conclusions:

• LT4 suppressive therapy demonstrates clear efficacy in achieving thyroid nodule reduction.
• Given the favorable efficacy and low incidence of adverse events, LT4 may be an appropriate intervention for carefully selected patients with a low risk of adverse effects.